ARCH Venture Partners XII, LLC bought $19.8M of Seaport Therapeutics (SPTX)
Executed May 4, disclosed May 4, the same day.
Over the 21 trading sessions from the disclosed entry session (May 4), the stock returned -10.2% (delay-adjusted); from the execution session (May 4), -10.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
ARCH Venture Partners XII, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Neumora Therapeutics, Inc. (NMRA). Across 2 priced purchase filings, the average 21-session return was -14.8% from execution and -11.1% from disclosure (delay-adjusted; derived). The largest single filing was $19.8M of SPTX (1,100,000 sh × $18.00, as filed), executed May 4.
Healthcare · Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depr…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→